AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Despite the EU and US agreeing a basic trade deal on Monday, the FTSE 100 and some European stocks fell on the day after a ...

AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical ...

Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of ...

This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

Wall Street stocks had a mixed session overnight, with the Dow Jones dipping 0.1%, the S&P 500 just one point above flat and ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

(Alliance News) - AstraZeneca PLC on Tuesday reported better-than-expected second quarter revenue, and raised its dividend, boosted by strong sales from its cancer portfolio.